In January 2011, XOMA announced an agreement with Servier to jointly develop and commercialize gevokizumab. Key elements of this agreement include:
XOMA has been awarded four contracts since 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance biodefense-related product development with anti-botulism neurotoxin monoclonal antibodies. Total potential funding under these contracts is approximately $120 million. The botulinum toxin, which causes botulism poisoning, is one of the most toxic poisons and is classified as a Class A, the highest level, bio-terror threat by the U.S. government.
XOMA has earned revenue from multiple licensing agreements and development collaborations related to its antibody technologies. XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS ® (ranibizumab injection) for wet age-related macular degeneration and CIMZIA ® (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
The company has a premier antibody discovery and development platform that incorporates leading capabilities in antibody phage display, library construction, proprietary antibody humanization and affinity enhancement and Bacterial Cell Expression (BCE) technologies. BCE was a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, 60 pharmaceutical and biotechnology companies have signed licenses to XOMA’s BCE technology.